Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T. Dubeau
Ibrutinib Monotherapy Produces Long-Term Disease Control in Previously Treated Waldenstrom's Macroglobulinemia. Final Report of the Pivotal Trial (Nct01614821).
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
Clinical Cancer Research
Cancer Research
Oncology
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
Clinical Cancer Research
Cancer Research
Oncology
OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) in Previously-Treated Malignant Mesothelioma (MM): Final Analysis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Long-Term Follow-Up of the RESONATE™ Phase 3 Trial of Ibrutinib Versus Ofatumumab
Blood
Biochemistry
Immunology
Cell Biology
Hematology
A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenstrom Macroglobulinemia
Clinical Cancer Research
Cancer Research
Oncology
Ofatumumab Monotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Final Results From a Pivotal Study
Haematologica
Hematology
PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
IgM Myeloma: An IgM Gammopathy Distinct From Waldenstrom's Macroglobulinemia
Hematology
Hematology
Diagnostic Tools of Waldenström’s Macroglobulinemia – Best Possibilities for Non-Invasive and Long-Term Disease Monitoring
Klinicka Onkologie
Oncology
